Co-injection of β-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons

Neuroscience

Volumn 84, Issue 2, 1998, Pages 479-487

  Morimoto, K ^a   Yoshimi, K ^a   Tonohiro, T ^a   Yamada, N ^a   Oda, T ^a   Kaneko, I ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

amyloid; Alzheimer's disease; Animal model; Co injection; Excitatory amino acid; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; ANTIBODY; DIZOCILPINE; DNA FRAGMENT; EXCITATORY AMINO ACID; EXCITATORY AMINO ACID RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IBOTENIC ACID; MICROTUBULE ASSOCIATED PROTEIN 2;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; DRUG SYNERGISM; HIPPOCAMPUS; IBOTENIC ACID; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; NEUROTOXINS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0031915038     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00507-1     Document Type: Article

References (37)

1. Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C.-M., Kim G., Seekins S., Yager D., Slunt H. H., Wang R., Seeger M., Levey A. I., Gandy S. E., Copeland N. G., Jenkins N. A., Price D. L., Younkin S. G., Sisodia S. S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
2. Chandrasekaran K., Hatanpaa K., Brady D. R., Rapoport S. I. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Expl Neurol. 142:1996;80-88.
3. Choi D. W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7:1987;369-379.
4. Cotman C. W., Anderson A. J. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Molec. Neurobiol. 10:1995;19-45.
5. Davies C. A., Mann D. M. A., Sumpter P. Q., Yates P. O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. neurol. Sci. 78:1987;151-164.
6. Dayan A. D. Quantitative histological studies on the aged human brain. II. Senile plaques and neurofibrillary tangles in senile dementia (with an appendix on their occurrence in cases of carcinoma). Acta neuropath., Berlin. 16:1970;95-102.
7. Dornan W. A., Kang D. E., McCampbell A., Kang E. E. Bilateral injections of βA(25-35)+IBO into the hippocampus disrupts acquisition of spatial learning in the rat. NeuroReport. 5:1993;165-168.
8. Flood J. F., Morley J. E., Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with Alzheimer's disease. Proc. natn. Acad. Sci. U.S.A. 88:1991;3363-3366.
9. Frautschy S. A., Baird A., Cole G. M. Effects of injected Alzheimer β-amyloid cores in rat brain. Proc. natn. Acad. Sci. U.S.A. 88:1991;8362-8366.
10. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montaya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan, H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
11. Games D., Khan K. M., Soriano F. G., Keim P. S., Davis D. L., Bryant K., Lieberburg I. Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol. Aging. 13:1992;569-576.
12. Geula C., Wu C.-K., Saroff D. M., Lorenzo A., Yankner B. A. A primate model of β amyloid-induced neurotoxicity and tau phosphorylation. Neurobiol. Aging. 17:1996;S200.
13. Glenner G. G., Wong C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. biophys. Res. Commun. 122:1984;1131-1135.
14. Goate A., Chartier-Harlin M. C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706.
15. Golde T. E., Estus S., Younkin L. H., Selkoe D. J., Younkin S. G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 255:1992;728-730.
16. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
17. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann. N.Y. Acad. Sci. 640:1991;53-58.
18. Kaneko I., Yamada N., Usui Y. and Oda T. (1997) Possible involvement of β-amyloids racemized at Ser residue in Alzheimer's disease. In Alzheimer's Disease: Biology, Diagnoses and Therapeutics (eds Iqbal K., Winblad B., Nishimura T., Takeda M. and Wisniewski H.M.), pp. 519-528. John and Sons Ltd, Chichester.
19. Kaneko I., Yamada N., Sakuraba Y., Kamenosono M., Tutumi S. Suppression of mitochondrial succinate dehydrogenase, a primary target of β-amyloid, and its derivative racemized at Ser residue. J. Neurochem. 65:1995;2585-2593.
20. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736.
21. Kar S., Seto D., Gaudreau P., Quirion R. β-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16:1996;1034-1040.
22. Khoury J. E., Hickman S. E., Thomas C. A., Cao L., Silverstein S. C., Loike D. J. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature. 382:1996;716-719.
23. Koh J. Y., Yang L. L., Cotman C. W. β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
24. Kowall N. W., Kosik K. S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann. Neurol. 22:1987;639-643.
25. Kowall N. W., Beal M. F., Busciglio J., Duffy L. K., Yankner B. A. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. natn. Acad. Sci. U.S.A. 88:1991;7247-7251.
26. Kowall N. W., McKee A. C., Yankner B. A., Beal M. F. In vivo neurotoxicity of beta amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol. Aging. 13:1992;537-542.
27. Mann D. M. A., Yuonis N., Jones D., Stoddart R. W. The timeline of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4. Neurodegeneration. 1:1992;201-215.
28. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. natn. Acad. Sci. U.S.A. 82:1985;4245-4249.
29. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R. E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389.
30. Mattson M. P., Rydel R. E. Alzheimer's disease. Amyloid ox-tox transducers. Nature. 382:1996;674-675.
31. Maurice T., Lockhart B. P., Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:1996;181-193.
32. Pike C. J., Walencewicz A. J., Glabe C. G., Cotman C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314.
33. Schenk D. B., Rydel R. E., May P., Little S., Panetta J., Lieberburg I., Sinha S. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J. med. Chem. 38:1995;4141-4154.
34. Stein-Beherens B., Adams K., Yeh M., Sapolsky R. Failure of beta-amyloid protein fragment 25-35 to cause hippocampal damage in the rat. Neurobiol. Aging. 13:1992;577-580.
35. Wisniewski K. E., Wisniewski H. M., Wen G. Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.
36. Yan S. D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A. M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
37. Yankner B. A., Duffy L. K., Kirschner D. A. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.